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Abstract
In this manuscript we apply stochastic modeling to investigate the risk of
reactivation of latent mycobacterial infections in patients undergoing treatment
with tumor necrosis factor inhibitors. First, we review the perspective proposed
by one of the authors in a previous work and which consists in predicting the
occurrence of reactivation of latent tuberculosis infection or newly acquired tu-
berculosis during treatment; this is based on variational procedures on a simple
set of parameters (e.g. rate of reactivation of a latent infection). Then, we de-
velop a full analytical study of this approach through a Markov chain analysis
and we find an exact solution for the temporal evolution of the number of cases
of tuberculosis infection (re)activation. The analytical solution is compared with
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Monte Carlo simulations and with experimental data, showing overall excellent
agreement. The generality of this theoretical framework allows to investigate
also the case of non-tuberculous mycobacteria infections; in particular, we show
that reactivation in that context plays a minor role. This may suggest that,
while the screening for tuberculous is necessary prior to initiating biologics, when
considering non-tuberculous mycobacteria only a watchful monitoring during the
treatment is recommended. The framework outlined in this paper is quite general
and could be extremely promising in further researches on drug-related adverse
events.
1 Introduction
Over the last decades the improved understanding of the pathogenesis of chronic in-
flammatory diseases, together with a major advance in biotechnology, have accelerated
the development of biological therapies, designed to neutralize specific targets that me-
diate and sustain the clinical manifestations of diseases. These compounds, mainly
monoclonal antibodies (mAb) and fusion proteins, introduced a breakthrough in the
management of different conditions including inflammatory rheumatologic disorders [1].
In this context, the first setting of application of the biological agents was rheumatoid
arthritis (RA), a chronic autoimmune disease affecting approximately 1% of the adult
population [2]. If the disease is not treated adequately, progressive deformity can lead to
loss of quality of life and reduce average life expectancy by about a decade [2]. Studies
on the pathogenic mechanisms of RA have revealed that tumor necrosis factor (TNF)
is a cytokine playing a critical role in the inflammatory cascade that results in the
irreversible joint damage typical of the disease [3]. Following these discoveries, a series
of clinical trials in patients with RA showed the therapeutic benefit of TNF blockade
[4]. As a consequence, five biological agents engineered to block TNF actions are cur-
rently available: infliximab, adalimumab, golimumab, certolizumab pegol (all of them
mAb), and etanercept (a receptor fusion protein) [5]. While being highly effective,
TNF blockers have raised concerns about the potential for an increased susceptibil-
ity to infections, in particular the reactivation of latent tuberculosis (TB) infection
[6, 7, 8, 9, 10]. Mycobacterium tuberculosis, the cause of human TB, can result in a
metastable clinical latency lasting for decades. Much has been speculated about the
structure of granuloma which should contain Mycobacteria, since murine models in-
dicated that TNF was necessary for both formation and maintenance of granulomas
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[11]. However, subsequent studies on zebrafish model [12], monkeys [13], and humans
[14, 15, 16, 17] challenged these data, demonstrating that the crucial role of TNF in the
granuloma was indeed macrophage activation and stimulation of chemokine production.
The reactivation of latent TB infection has been associated with all TNF inhibitors,
hence pre-initiation screening procedures have been recommended, which have success-
fully reduced the number of reported cases [18], although current screening tools lack
sensitivity and specificity [19, 20].
TNF blockers seem to increase also the risk of other granulomatous diseases, but
little is known about the emergence of illness due to non-tuberculous Mycobacteria
(NTM). These are a huge ensemble of pathogens (e.g. M. avium, M. abscessus, and so
on [21]) and up to date, approximately 50 different mycobacterial species are considered
to be etiological agents of human diseases and this number seems still growing [21]. Most
cases these days occur in hosts with relatively intact immune responses. However, RA
and other chronic diseases with pulmonary manifestations can predispose a person to
NTM pulmonary disease [22] expressing as a possible serious complication, especially
in immunosuppressed subjects. Thus, it is of utmost importance to study also the
risk related to NTM, in the perspective to understand if a proper screening may be
helpful in conferring a wider protection to the patients. This is particularly true, in
that the TNF blockers appear to predispose both to disseminated and localized disease
[23, 21], but also because these infections are increasing in prevalence, especially among
women, which are more frequently affected by RA than men. In the present state of the
art, the scenario for NTM diseases, with respect to TNF-blocking drugs, seems different
from the TB counterpart: in particular, through extensive experimental screening, both
Wallis and coworkers [10], and Winthrop and coworkers [23, 24] evidenced that latency
and reactivation do not seem to play a crucial role in this context, yet a clear-cut picture
is still missing.
Now, as far as TB is concerned, data collected through the Adverse Event Reporting
System of the US Food and Drug Administration (FDA) in the time-window 1998−2002,
related to the two test-case drugs with a different mechanism of action, i.e. infliximab
and etanercept, highlight that TB infections involve 54 over 105 patients treated with
infliximab and 28 over 105 patients receiving etanercept [10]. Therefore, the question
is: As the latency in TB can last decades, are these infections (in patients under
therapy) new ones or are they reactivation of previously encountered pathogens due
to a suppressed immune system? This kind of question underlies the awareness of
a real need and disposal for extensive pre-screening procedures. Unfortunately, the
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answer is by far not trivial as, for TB, there are no secure pathways to discriminate
between a new infection or the raise of a previous one. Moreover, a clear methodology
for finding latencies is still lacking. Furthermore, the rarity and different sizes of this
infection in different countries (ranging from 5 over 105 in Sweden up to 140 over 105
in Romania [8]) implies that data analysis and its subsequent interpretation must be
carefully performed.
As for NTM, still from FDA, through the post-marketing surveillance system (Med-
Watch) and through a further survey within the Emerging Infections Network of the
Infectious Diseases Society of America (IDSA), Winthrop and coworkers reported a
detailed study of possible correlations between the usage of TNF blockers and the
emergence of NTM diseases: over a time-window of 8 years, they highlighted a higher
prevalence of NTM diseases in patients treated with infliximab rather than etanercept
[24].
In order to investigate possible correlations between the incidence of infections by
such Mycobacteria and biological therapy, one could rely directly on the molecular
details of TNF processing signal (which has been, at least partially, elucidated, see
e.g. [25]), coupled to the underlying infliximab and etanercept mechanism of action,
which could be achievable directly through molecular immunology approach. Beyond
these “standard” strands, a completely different route can also be performed: Given
the relative large amount of collected data, the problem can be considered from a
purely inferential viewpoint, by-passing the underlying molecular immunology know-
how (see also [26, 27]). According to this perspective, in Ref. [9, 10], an abstract
(logical) environment for TB case has been defined, where patients can occupy one of
the (following) five different states: (0) No infection, (1) New infection, (2) Latency,
(3) Reactivation of a previous TB infection, (4) Post first TB encounter. Clearly, the
patients starting the therapy (and hence belonging to the survey) can correspond to
either state (0) or (2), because all the other states imply quantifiable sickness and the
patient would then be treated for TB rather than RA. Then, at the end of the survey,
a fraction of these patients will be in an illness state, i.e. either state (3) or (4). The
transition rates between different states are assumed as free-parameters, whose values
are estimated through numerical simulations: the best estimate is the one able to
reproduce, with the smallest error, the experimental data. Remarkably, the probability
of latent TB reactivation in patients treated with infliximab turned out to be an order
of magnitude per unit of time higher than the same probability for patients trated with
etanercept [9].
4
Here, we first formalize this approach in terms of Markov chains and we write the
related Master equation in continuous-time limit, then we solve the model analytically
and study its properties in full details. In this way we get the explicit expression for the
number of patients c(t) exhibiting a TB (re)activation, as a function of time t. One step
forward, we check the robustness of our results through extensive Monte Carlo simula-
tions and over the clinical data of the TB scenario, finding overall excellent agreement
among all our results (and previous literature). Moreover, we find that different mag-
nitudes for the probability of reactivation correspond to qualitative different behaviors
for c(t) (on the proper timescale), that is, the number of patients displaying active in-
fection increases exponentially in time when using infliximab and linearly in time when
using etanercept.
The analytical expression for the whole evolution of the system implies a great
feasibility of the technique itself (e.g. we have the whole set of first integrals and a clear
picture of all the hidden symmetries) and also allows to address, in complete generality,
several instances. In particular, we can finally consider generic NTM infections, where,
interestingly, the scenario appears quite different from the TB counterpart: clinical
data suggest that c(t) (on the proper timescale) grows quadratically with time and this
is recovered by our analytical picture only under the assumption of a negligible role
played by latency reactivation. We check these findings also through extensive Monte
Carlo runs, which are in full agreement too. Remarkably, this is very consistent with
the present state of the art in the medical literature dealing with NTM.
As a final result, there are two types of conclusions which stem from our work: The
former belongs to the world of modelers, while the latter to the world of clinicians.
From a mathematical perspective, the encouraging results of this approach may pave
the way for the development of handily and fruitful instruments for physicians.
Much more carefully, in the clinician’s counterpart, as this approach bypasses the whole
underlying biological complexity, it may contribute to confirm, from a theoretical per-
spective, the current understanding of adverse events coupled to TNF-inhibitors and the
consequent real need for screening procedures before undergoing biological therapies.
2 Material and methods
In this section we formalize the scheme introduced in [9] and aimed to reproduce data
of TB onset in patients treated with TNF inhibitors, with particular attention on
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infliximab (an anti-TNF mAb) and etanercept (a soluble TNF receptor). Seeking for
clarity, in this section we mention only applications to the TB case, although, as we
will see in the second part of the paper, the approach is rather robust and can be
successfully applied to the NTM case, too.
The model, whose structure is depicted in Figure 1, consists in identifying a set
of possible states for the patient subjected to biological treatments, and in fixing the
likelihood for the patient to change his/her state within a proper unit time 1.
The clinical states available to a test-patient are taken as follows (see Figure 1):
0 : Absence of infection;
1 : New infection (that after a time τ can give rise either to active TB or latent
infection);
2 : Latent infection;
3 : Reactivated TB after latency;
4 : Active TB (that progress from new infection within a time τ , without an inter-
vening period of latency).
Moreover, each patient is assumed to change his/her state, following the corresponding
transition probabilities, which constitute the model parameter set, and are meant over
a proper unit time τ . Using t to label the time, these probabilities are:
L : Probability of having a latent infection at the beginning of the observation
(t = 0), while, obviously, (1−L) is the probability of not having any infection at
that moment;
N : Probability of TB infection during the observational time;
P : Probability of a new TB infection to become active TB after a time τ ; as a
consequence, (1 − P ) is the probability of this new infection to give rise to a
latent infection;
R : Probability of reactivation of a latent TB infection.
1Clearly, on large samples, some patients may experience sudden incidents (e.g. death for other
causes) or some others may assume both the drugs: the analysis has been previously purified from
these cases [9, 10].
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We stress that such probabilistic framework is based on purely clinical variables.
On the experimental side, the available data consist in a collection of times (one for
each patient) corresponding to the onset of TB (in its active phase, namely a detectable
scenario), after the beginning of the treatment with TNF blockers. As a consequence,
the only states which are possible to observe are the states 3 and 4. Unfortunately,
as discussed in the introduction, these states (that account for ill patients) are not
distinguishable one respect to the other by simply looking at the data (hence motivating
both earlier studies [9, 10] and our machinery), however, some progress can be made
using stochastic extremization. The idea resembles the standard maximum likelihood
and consists in finding the best values for free parameters such that the theoretical
curves collapse over the experimental data [28].
As already outlined, following this procedure, the main result in [9] is that the
principal difference between infliximab and etanercept treatments resides in different
management of latent TB, i.e. on R. The former seems to enhance reactivation one
order of magnitude more than the latter.
Markov chains and master equations
The model described in the previous section can be translated into a set of differential
equations coding for the temporal evolution of the probability of patient’s states (which
can be compared to the corresponding fractions over a sample of patients given the large
collection of data).
Being the states discrete, this can be accomplished in complete generality using
Markov chains, namely a (discrete-time) probabilistic framework where the probability
of being in a given state at a given time t depends only on the probability distribution
over all the states at the previous time step t − 1, and on the transition rates linking
these states.
It is instructive to consider the illustrative Markov chain with only three states (A,
B and C), non-null transition rates wA→B and wB→C and time step ∆t, shown in Figure
2.
Note that, in the model, the probabilities of going from A to B and from B to
C exist but not the opposite (wB→A = 0, wC→B = 0) hence, if the initial state is
all concentrated in C, there will be no evolution, while if the starting point is spread
among A and B, after enough time, the probability distribution will be peaked on C
only (but in its finite temporal evolution resides our interest).
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Now, the probability of remaining-at/moving-into the state B in the time interval
∆t is given by the probability of already being in B (hence pB(t)) plus the probability
of arriving in B from A times the probability of being in A at the previous step (hence
wA→BpA(t)) minus the probability of leaving B to C times the probability of being in
B at the previous step (hence wB→CpB(t)); this concept can be written as follows:
pB(t+ ∆t) = pB(t) + pA(t)wA→B∆t− pB(t)wB→C∆t . (1)
Since the mathematics for continuous variable differential equations is much more hand-
ily and does not change significantly the perspective if the time step is small with respect
to the global time window2, we are allowed to consider the time as a continuous vari-
able. This can be achieved straightforwardly starting from the previous equation using
a limit procedure:
lim
∆t→0
pB(t+ ∆t)− pB(t)
∆t
=
dpB(t)
dt
= pA(t)wA→B − pB(t)wB→C .
The evolution for the probability pB(t) is then ruled by the following differential equa-
tion, namely a “Master equation”, which acts as a continuous counterpart of the Markov
chain in the discrete-time case:
dpB(t)
dt
= pA(t)wA→B − pB(t)wB→C . (2)
In general, for a system which can be in one of M arbitrary states, we need a M ×M
transition-rate matrix w (where wi→j is the rate for the transition from state i to state
j) and the Master equation takes the form
p˙i(t) ≡ dpi
dt
=
M∑
j=1
wj→i pj(t)−
M∑
j=1
wi→j pi(t) . (3)
Note that we use the symbol · above the functions meaning their temporal derivative.
Finally, we switch to a form where the explicit timescale τ of the process appears
2Both the experimental data set considered here (for TB cases [10] and for NTM cases [23]) fulfill
this requirement.
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directly in the equation, that is
τ p˙i(t) =
M∑
j=1
Wj→i pj(t)−
M∑
j=1
Wi→j pi(t), (4)
where Wi→j ∼ wi→jτ stands for the probability of transition from state i to j along the
time interval τ .
Master equations for the model
Keeping in mind Figure 1, we can write down the system of differential equations
describing the evolution of the five states earlier introduced as follows:
τ p˙0 = −N p0(t),
τ p˙1 = Np0(t)− p1(t),
τ p˙2 = (1− P ) p1(t)−Rp2(t),
τ p˙3 = Rp2(t),
τ p˙4 = P p1(t),
(5)
with initial conditions
p0(t = 0) = 1− L,
p2(t = 0) = L,
p1(t = 0) = p3(t = 0) = p4(t = 0) = 0.
(6)
The numbers indexing the probabilities mirror the enumeration of the previous section,
that is, p0 stands for the probability that a patient has never been affected by the infec-
tion, and so on. The parameter τ represents the typical time for a patient experiencing
a new infection to either develop the disease or to fall into a latent state and it should
be chosen according to the natural time-scale of the process described. For instance,
for the TB case, the data collected suggest that τ is order of a few months [10, 29], and
we set τ = 1month for the sake of simplicity and in agreement with previous works
[9, 10].
Note that, as patients affected by active TB do not start RA therapy, we set p1(t =
0) = p3(t = 0) = p4(t = 0) = 0. Furthermore, the parameter L tunes the initial
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amount of latent-TB patients with respect to free-TB patients, such that for L = 0 all
patients are healthy, while for L = 1 all patients display a latent TB infection; as we
have no ways to discriminate between healthy and latent-infected patients, L is taken
as a free parameter which can be estimated a posteriori comparing the solution of (5)
with available data.
The solution of the system (5) can be easily obtained using first order ordinary
differential equations theory and reads off as
p0(t) = (1− L) e−Nt/τ ,
p1(t) = N
1−L
1−N
(
e−Nt/τ − e−t/τ) ,
p2(t) = − (1−P )(1−L)N(1−N)(N−R) e−Nt/τ +
[
L+ (1−P )(1−L)N
(N−R)(1−R)
]
e−Rt/τ + (1−P )(1−L)N
(1−N)(1−R) e
−t/τ ,
p3(t) = L+ (1− P )(1− L) + R(1−P )(1−L)(1−N)(N−R) e−Nt/τ −
[
L+ (1−P )(1−L)N
(1−R)(N−R)
]
e−Rt/τ
− (1−P )(1−L)RN
(1−N)(1−R) e
−t/τ ,
p4(t) = P
1−L
1−N
(
1−N − e−Nt/τ +N e−t/τ) .
(7)
Of course, since the total amount of patients is conserved, C0 = p0 + p1 + p2 + p3 + p4
is an integral of motion, that is
0 =
d
dt
C0 ⇒ C0 = p0(t) + p1(t) + p2(t) + p3(t) + p4(t) = const. (8)
Beyond C0, the system (5) admits another integral of motion C1, namely
0 =
d
dt
[
p2(t) + p3(t) +
P − 1
P
p4(t)
]
⇒ C1 = p2(t) + p3(t) + P − 1
P
p4(t) = const. (9)
This means that the rate of growth for patients in the latency branch (i.e. in states
2, 3) equals the rate of growth for the rest of infected patients (i.e. in state 4) weighted
by a factor P−1 − 1, so that the smaller P and the larger the difference between the
related rates. The knowledge of integrals of motion can be very useful as they allow to
obtain information in a very simple way; for instance, should P drop, then p4(t) would
also decrease (or, analogously, p2(t) + p3(t) would increase) in order to maintain C1
constant. Given C0 and C1, other integrals of motion, which are combination of C0 and
C1, can be trivially built. For example, C2 = C0 − C1 fulfills
0 =
d
dt
[
p1(t) + p0(t) +
1
P
p4(t)
]
⇒ C2 = p1(t) + p0(t) + 1
P
p4(t) = const. (10)
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We underline that this kind of investigation can be accomplished only through an
analytical study of the system.
As discussed above, the fraction of active TB cases is given by the sum of the fraction
of cases of direct TB after infection and of the fraction of cases with reactivated TB;
namely, calling c(t) the total fraction of cases, we have:
c(t) = p3(t) + p4(t) . (11)
In the above quantity, the time dependence appears only through three different ex-
ponential decay terms (e−Nt/τ , e−Rt/τ , e−t/τ ), which vanish at infinite time, so that
the solution becomes a constant term equal to 1, meaning that, if we wait for a suffi-
cient long (possibly infinite) time, all patients become sick (although, obviously, they
can possibly die earlier due to reasons not related to RA/TB). In order to deepen the
temporal evolution of these probabilities at relatively short times, it is useful to use a
little bit of algebraic manipulation to distinguish constant terms from decaying terms,
in such a way that we get
c(t) = 1 + k1e
−t/τ + kRe−Rt/τ + kNe−Nt/τ , (12)
where the three constants k1, kR and kN are related to the physiological parameters by
k1 =
N(1−L)(P−R)
(1−N)(1−R) ,
kR = −L+ N(1−P )(1−L)(1−R)(R−N) ,
kN = − (1−L)(R−PN)(1−N)(R−N) .
(13)
Of course, from c(t) one can derive the effective number of cases multiplying c(t) by
the overall number of treated patients.
Before turning attention to the fitting procedure, we stress that the analytical solu-
tion in Eq. (7) was successfully checked through numerical methods, i.e. fourth-order
Runge-Kutta algorithm and Monte Carlo simulations3.
3Here, with Monte Carlo simulation we mean a simulation in which a set of virtual patients evolves
in time following the Markov chain of Figure 1 giving a sample of the evolution of the fraction of cases
during time. In our simulations we set 106 virtual patients.
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3 Results
The TB-infection case
Having obtained the complete solution of the model and exploiting the available in-
formation on parameters, we now look for proper approximations able to highlight the
effective behavior of c(t) in cases of practical interest, starting with the TB scenario.
In particular, Eq. (12) can be reduced to a simpler form if we note that the prob-
ability N of TB infection is much smaller than all the other parameters, in agreement
with studies on TB and with results found in [9] and, a posteriori, in the current paper
(see Tab. 1).
Hence, as a first approximation step, we assume N  1 and N/R 1 such that we
can expand the solution, at the first order in N and N/R, as follows4:
k1 = (1− L)
(
P −R 1− P
1−R
)
N [1 +N +O(N2)],
kR = −L+ (1− P )(1− L)
R(1−R) N
[
1 +
N
R
+O
(
N2
R2
)]
,
kN = −(1− L)
{
P [1 +N +O(N2)] + (1− P )[1 +N +O(N2)]
[
1 +
N
R
+O
(
N2
R2
)]}
.
Therefore, with some algebra and retaining only up-to-linear terms in N or N/R, we
get
c(t) ≈ 1 +N(1− L)P −R
1−R e
−t/τ +
[
−L+ (1− P )(1− L)
1−R
N
R
]
e−Rt/τ
− (1− L)
[
1 +N +
N
R
(1− P )
]
e−Nt/τ . (14)
Let us now move further and focus on the exponential terms. First, we notice that
1 > R > N and, consequently, we can neglect the term e−t/τ , as it decays much faster
that both e−Rt/τ and e−Nt/τ . Moreover, since the time range considered is ≈ 30 months
and N is expected to be  τ/t ≈ 10−2, we can expand e−Nt/τ as e−Nt/τ ≈ 1 − Nt/τ ,
4Here and in the following we use the “big-O” Landau notation to characterize the growth rate
of functions; more precisely, being f(x) and g(x) two arbitrary functions, we say f(x) = O(g(x)) as
x→ 0 if there exists a positive real number M such that |f(x)| ≤M |g(x)|.
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and considering only the leading dependence on t, we get
c(t) ≈ 1− (1− L)
[
1 +N +
N
R
(1− P )
]
+
[
−L+ (1− P )(1− L)
1−R
N
R
]
e−Rt/τ . (15)
As for e−Rt/τ , a similar approximation (e−Rt/τ ≈ 1 − Rt/τ) can be adopted as long as
R . 10−2, so to obtain the following linear approximation
c(t) ≈ 1 + kR(1−Rt/τ) + kN . (16)
Notice that a smaller (larger) estimate for τ would simply require a stricter (softer)
condition on N and on R for the related linear expansions to hold (on the same time
range); the model would not be affected and the parameters coupled with time, i.e.
N,R, would be accordingly rescaled. As shown in Figure 3, the approximation (16) is
rather good only for etanercept-treated patients, for which the best fit yields R = 2.24 ·
10−2. On the other hand, if we consider infliximab-treated patients, the approximation
(16) does not fit data, while using (15) we get a good overlap with data and the best
fit yields R = 2.12 · 10−1, confirming that now Rt/τ is no longer small over the time
window. All best-fit coefficients are reported in Tab. 1, and the related errors are shown
in Figure 4.
We can estimate how sensitive c(t) is with respect to the system parameters by
deriving its analytic expression (see Eq. 12) with respect to N,P,R, L, respectively;
in this way we get that, in the regime N  (1, P, R, L), the most relevant parameter
affecting the behavior of c(t) is R. Another argument in favor of this claim is that, in
the zero approximation of the solution (i.e. neglecting even terms O(N)), P does not
appear at all.
In order to get further insight on the effect of infliximab and of etanercept on TB
incidence, in Fig. 5 we plotted the model predictions for the percentage of patients
having TB because of new infections (p4(t)) or reactivations (p3(t)).
To summarize, our results confirm that, in the present context, the most important
difference between therapies based on infliximab or etanercept is that the former en-
hances TB reactivation more than the latter, in fact, we found RINF ∼ 10RETA, in
agreement with [9]. Such a discrepancy implies even a qualitatively different behav-
ior of c(t) over the time-window considered: the number of infliximab-treated patients
experiencing a TB infections grows exponentially in time, while for etanercept-treated
patient the growth is linear.
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The NTM-infection case
The analytical expression for c(t), (see Eqs. 7 and 11) holds for a general environment
schematizable as in Fig. 1; in the last paragraph we used the details of TB infections
to implement convenient approximations. We now turn to NTM-infections in patients
treated with infliximab and etanercept and look for proper approximations able to
highlight the characteristic features of such case. The experimental data we refer to are
those reported in [23] and collected over the period 1999 − 2006. Overall, there were
239 reports of NTM infections in patients who were receiving anti-TNF therapy. Most
reports were for patients receiving infliximab (75%) or etanercept (17%) and here we
shall focus just on these drugs.
Some remarks are in order here to merge mathematically the TB and NTM scenarios.
First, it is important to notice that patients affected by NTM lung infections typi-
cally suffer through long periods of illness before a clinical diagnosis is made. To comply
with the actual state of the art on the involved time-scales we follow M. Iseman and T.
Marras [29] that we quote: “Preliminary prevalence estimates have been made, assum-
ing that the disease duration for TB is 8 months and for pulmonary NTM is within the
range of 4 to 10 years” (48 to 120 months), hence for NTM the timescale is at least one
order of magnitude larger than in the TB counterpart.
Another important point is that available data on NTM-diseases related to drug
therapies lack the size of the survey, namely the number of patients participating to the
screening, consequently, we can quantify the (cumulative) amount of sick patients, but
we do not know their percentage. This is not a serious deficiency since, while we do
not have access to the very reactivation probabilities RINF or RETA, their ratio (which
cancels out both time-scales and survey-size) still retains a quantitative information
content.
As a result of the first remark, the (average) exit time from state 1, i.e. τ , is
comparable to the experimental time window, and one can expand the solution reported
Eq. 7 at second order in t/τ as
p3(t) = RL
t
τ
− LR2 t
2
2τ 2
+O
(
t3
τ 3
)
, (17)
p4(t) ≈ PN(1− L) t
2
2τ 2
+O
(
t3
τ 3
)
. (18)
We notice that, at this stage of expansion, p4(t) grows quadratically with time, while
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p3(t) presents two contributes growing, respectively, linearly and quadratically with
time, the former being the leading one.
Such expressions must now be compared with experimental data, which display a
purely quadratic growth in time, i.e. compatible with c(t) = at2 (see Fig. 6). In order
for the comparison to hold, one must therefore drop the linear coefficient, and this
implies R ∼ 0 (or L ∼ 0 which is conceptually pretty similar). With this choice of
parameters we get
p3(t) ≈ 0
p4(t) ≈ PN t22τ2
⇒ c(t) ≈ PN t
2
2τ 2
, (19)
and this form successfully fits experimental data, as shown in Figure 6; the best-fit
coefficients are reported in Tab. 2, and the related errors are shown in Figure 7.
The functional form of p4(t) highlights why finding an estimate of the parameters
is extremely difficult through blind numerical extremization, without any explicit an-
alytical hint: The latency-branch turns out to be negligible in NTM-context and this
results in a coupling of the parameters P and N as only a single probability streaming
toward p4(t) survives. Therefore the two parameters alone are undetectable.
Using the coefficients of Tab. 2 in numerical simulations we obtain results in excellent
agreement with real data and analytical ones. Notice that, impressively, the fit is very
good although here the optimization relies only on one parameter.
We stress that the qualitative difference between the behaviors of c(t) in the case
of TB and NTM infection (see Eqs. 15 and 19) mainly stems from a significant gap in
the related disease duration (few months versus several years). In the latter case τ is
relatively large to allow the expansion of the exponential functions into a polynomial
form, while for TB this can be accomplished only under the condition of small enough
R. Such expansions do not significantly alter the predicted values of the fit parameters,
as long as the underlying assumptions are consistent with facts.
To summarize, the theoretical framework developed evidences that the rate of reac-
tivation R is vanishing: This issue makes the fraction p3 of reactivation cases negligible,
while the number of activation cases grows quadratically with time through the con-
tribution of only p4, consistently with the actual understanding of NTM-pathology
achieved through standard pathways. Moreover, differently from the TB case, in the
NTM scenario no qualitative difference can be detected between infliximab and etan-
ercept: The parabolic behavior for c(t) seems robust.
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4 Discussion
In the last decades, several tools and concepts stemmed from the fields of stochastic
mathematics and theoretical physics have been proposed to help the investigation of the
immunological world, ranging from kinetic theories [30], to associative neural networks
[31, 32], to cellular automata and more [33, 34].
Along the same line, in these notes we formalized and extended a stochastic ap-
proach to data analysis (originally introduced in [7, 8, 9, 10]) for evidencing underlying
correlations between adverse events and therapies based on immunosuppressants. In
particular, the focus of our investigation concerns the risk of reactivation of latent
mycobacterial infection in patients undergoing treatment with TNF-inhibitors.
We gave a clear and complete mathematical backbone to this approach, building it
on explicit Markov processes, whose continuous-time limit yields the Master equation
governing the evolution of the expected fraction of patients c(t) exhibiting an active in-
fection. We also solved the Master equation in all details finding an analytical expression
for c(t). Such mathematical developments make the original approach much more ver-
satile and general: For instance, handling the complete (mathematical) solution allows
to better account for reasonable approximations, tackling their control quantitatively
(e.g. finding the proper timescales involved in the process or the integrals of motion
constraining the evolution of the system). Furthermore, we can finally consider, within
the same framework, different problems. In particular, we focused on TB and NTM
infections emerging during anti-TNF therapies (infliximab and etanercept) according
to data reported in [9, 23].
In the former case, we recovered previous findings showing that the rate of reac-
tivation R of TB from a latent state to an active state plays a crucial role: being
RINF ∼ 10RETA we get qualitatively different behaviors for c(t). More precisely, once
fixed the observational time-window, for infliximab c(t) grows exponentially with time,
while for etanercept it grows linearly with time. Hence, these results sustain the need,
for patients candidate to TNF blockers, to perform an accurate TB screening at base-
line, irrespective of the type of antiTNF. Indeed, screening may decrease the risk of
TB reactivation in such patients, while it is less clear what should be done to prevent
NTM disease occurrence or progression in patients taking biologic agents. Importantly,
for this purpose, we found that the comparison with experimental data allows to infer
that reactivation plays a very minor role for both the therapies and that c(t) grows
quadratically with time.
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We checked our results also against Monte Carlo simulation with excellent agree-
ment.
Furthermore, our results are all consistent with recent experimental data and seem
to indicate that TB and NTM infections are sustained by different pathogenetic mech-
anisms.
Non-tuberculous Mycobacteria are present in large numbers in the environment,
including fresh water, aerosols, biofilms, and soils [35]. There are thus many opportuni-
ties for acquisition of NTM infection during ordinary daily activities, although the true
incidence is not known. In contrast, nearly all transmission of Mycobacterium tubercu-
losis infection results from inhalation cough-generated aerosols from persons with active
pulmonary TB. The annual risk of TB infection (ARTI) can be calculated from age-
specific rates of tuberculin skin test reactivity; in most instances it is directly related to
TB prevalence. Thus although the ARTI may reach 4% in highly TB-endemic regions
such as South Africa, it is as low as 0.01% in much of Northern Europe and North
America [36, 37, 38]. These epidemiologic findings are consistent with the results of
our mathematical model, and underscore the interplay of microbial and host biology in
determining the relative contributions of reinfection and reactivation to mycobacterial
pathogenesis.
Hence, while the screening for TB is necessary prior to initiating biologics, when
considering NTM only a watchful monitoring during the treatment is recommended.
This finding is particularly relevant, since it allows to avoid screening for NTM infection,
which is complicated by the poor sensitivity of chest radiograph and more expensive
and invasive techniques, such as chest computed tomography scan and/or bronchoscopy,
should be used.
It is worth stressing that this methodology, being based on very standard stochastic
procedures, has the advantage to hold beyond the test case of Mycobacteria. We hope
that this test-case may shed light to future developments of this sideline approach in
figuring out adverse events of biological therapies.
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Figure Legends
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R
Figure 1: Symbolic representation of the Markov chain under investigation. States are
represented as circles and numbered from 0 to 4 according to the scheme outlined in the Material
and Methods section. The arrows N,P, 1− P,R represent the transition probabilities connecting two
different states, while 1− L and L represent the initial conditions on the states 0, 2.
wA    B
A B C
wB    C
Figure 2: Toy Markov chain. From the state A there is a potential flux of probability at rate
wA→B toward the state B, hence we expect that, after a proper amount of time, a fraction of the
probability p will be drained from A to B. The same holds for the situation linking C to B. After an
infinite time the probability of having the patient in the state C is one, while it is zero for the states
A,B.
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Figure 3: Comparison between experimental, analytical and numerical results for the
TB-infection case. Cumulative number of patients undergoing active TB-infection. Experimental
data from [9] (• for infliximab-treated patients and 4 for etanercept-treated patients) are compared
with the approximated analytical solution (see Eq. 15 and Eq. 16, respectively, solid curves) and with
data from numerical simulation (dashed curves). The parameters used to draw the analytical curves
correspond to the best-fit coefficients and are reported in Tab. 1. Notice that here we consider the
extensive number of patients affected by TB over a population of N = 105 treated patients, according
to experimental results.
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Figure 4: Deviations between experimental, analytical and numerical results for the TB-
infection case. Absolute difference between experimental data and theoretical data reported in Fig. 3;
the same legend holds.
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Figure 5: Probabilities p3 and p4 versus time for the TB-infection case. The probability
p3 of being in state 3 (TB reactivation) and p4 of being in state 4 (Post 1
◦ TB) are calculated from
Eq. 7, using the parameters of Tab. 1. In the main plot we compare the ratio p3/p4 obtained from
infliximab (•) and etanercept (4) parameters. In the inset, we depict each single probability, namely
p3 for infliximab (dark •) and for etanercept (dark 4), p4 for infliximab (bright •) and for etanercept
(bright 4); notice that the two sets of data for p4 are partially overlapped. Lines are guide for the eye.
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Figure 6: Comparison between experimental, analytical and numerical results for the
NTM-infection case. Cumulative number of patients undergoing active NTM-infection. Experi-
mental data from [23] (• for infliximab-treated patients and 4 for etanercept-treated patients) are
compared with the approximated analytical solution (see Eq. 19, solid curves) and with data from
numerical simulation (dashed curves). The parameters used to draw the analytical curves correspond
to the best-fit coefficient and are reported in Tab. 2. Notice that here we consider the extensive number
of patients affected by NTM over the whole population of treated patients, according to experimental
results.
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Figure 7: Deviations between experimental, analytical and numerical results for the
NTM-infection case. Absolute difference between experimental data and theoretical data reported
in Fig. 5; the same legend holds.
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Tables
TB-infection case: Best-fit coefficients.
L (4.52± 0.65) · 10−4
N (2.88± 0.23) · 10−6
RINF (2.12± 0.19) · 10−1
PINF (9.76± 0.82) · 10−1
RETA (2.24± 0.15) · 10−2
PETA (8.03± 0.71) · 10−1
Tab. 1. TB-infection case: Best-fit coefficients. Best fit parameters obtained
through the maximum likelihood method (see Eqs. 15, 16, respectively). Here we used
τ = 1month, consistently with clinical data. The fit was accomplished with the
constraint that the parameters N and L are the same for both therapies, as they are
drug-independent. The average relative error on these parameters is ≈ 9%.
NTM-infection case: Best-fit coefficients.
NPINF (5.88± 0.46) · 102/N
NPETA (1.59± 0.13) · 102/N
Tab. 2. NTM-infection case: Best-fit coefficients. Best fit parameters obtained
through the maximum likelihood method (see Eq. 19). Here we used τ = 10 years,
consistently with clinical data. Notice that here parameters only count through the
combination PN , and, again, N was thought as drug-independent. Moreover, in this
case available data are extensive, so that the explicit number of overall treated
patients N has been introduced. The average relative error on these parameters is
≈ 8%.
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